Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT Pre-market 09:01:48 am
1.4 USD 0.00% Intraday chart for Pacific Biosciences of California, Inc. 1.39 -0.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7 MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care MT
Pacific Biosciences of California Q1 Revenue Expected to Be Flat Year Over Year; Guidance Lowered; Shares Sink MT
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 CI
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating MT
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes CI
Transcript : Pacific Biosciences of California, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions CI
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating MT
Pacific Biosciences of California Q4 Non-GAAP Loss Narrows, Revenue Rises; Shares Drop After Hours MT
Transcript : Pacific Biosciences of California, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (PACB) PACIFIC BIOSCIENCES OF CALIFORNIA Reports Q4 Revenue $58.4M, vs. Street Est of $58.3M MT
Pacific Biosciences of California, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale CI
PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions CI
Transcript : Pacific Biosciences of California, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM
Pacific Biosciences Posts Higher Preliminary Q4, Full-Year 2023 Revenue MT
UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating MT
Guggenheim Initiates Pacific Biosciences of California With Neutral Rating MT
Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board CI
Pacific Biosciences of California Shares Rise After UBS Upgrade MT
UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13 MT
Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating MT
Chart Pacific Biosciences of California, Inc.
More charts
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
1.4 USD
Average target price
5.818 USD
Spread / Average Target
+315.58%
Consensus
  1. Stock Market
  2. Equities
  3. PACB Stock
  4. News Pacific Biosciences of California, Inc.
  5. Pacific Biosciences of California : Cantor Fitzgerald Adjusts Price Target on Pacific Biosciences of California to $25 From $16, Maintains Overweight Rating